Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study
Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14400-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238403087859712 |
|---|---|
| author | Merin Babu Ashok Sebastian Komaranchath Arun Valsan Arun R. Warrier Rakesh MP Wesley M. Jose Nikhil K. Haridas Sumi Soman Manjima P. Nair Shine Sadasivan Abhinav Menon Mohammed Thabrez Keechilat Pavithran |
| author_facet | Merin Babu Ashok Sebastian Komaranchath Arun Valsan Arun R. Warrier Rakesh MP Wesley M. Jose Nikhil K. Haridas Sumi Soman Manjima P. Nair Shine Sadasivan Abhinav Menon Mohammed Thabrez Keechilat Pavithran |
| author_sort | Merin Babu |
| collection | DOAJ |
| description | Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies. Patients and methods All patients diagnosed with advanced HCC who received systemic therapy with atezolizumab bevacizumab as the first- or second-line therapy were included in the study. Data were collected retrospectively from two comprehensive cancer centres between September 2020 and May 2024 by accessing the medical records. As per the IMBrave 150 trial, patients were given atezolizumab 1200 mg and bevacizumab 15 mg/kg intravenously every 3 weeks. Demographic details, adverse events, and radiological data were collected. Results We included one hundred and four patients with a median age of 67 years. Majority of the patients had a compensated cirrhosis (n = 77; 74%), while Child Pugh class B cirrhosis was observed in 19 patients (18%), and class C cirrhosis in 3 patients (3%). The median OS was 14.8 (95% CI; 6.8 – 22.9) months and median PFS in the whole cohort was 6.2 months (95% CI; 2.5 – 9.9) monthsGlobally, hepatocellular carcinoma (HCC) ranks sixth in incidence and third among cancer-related dea. Conclusion The real-world OS and PFS rates were lower than those of the IMBrave trial, most likely because 43% of our patients did not meet the inclusion criteria. We conclude that the combination of atezolizumab and bevacizumab is a safe and effective option for patients with unresectable hepatocellular carcinoma patients with manageable toxicities. |
| format | Article |
| id | doaj-art-b809f70ed00a42e8b3ee6002ee8e49bc |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-b809f70ed00a42e8b3ee6002ee8e49bc2025-08-20T04:01:36ZengBMCBMC Cancer1471-24072025-07-0125111010.1186/s12885-025-14400-9Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric studyMerin Babu0Ashok Sebastian Komaranchath1Arun Valsan2Arun R. Warrier3Rakesh MP4Wesley M. Jose5Nikhil K. Haridas6Sumi Soman7Manjima P. Nair8Shine Sadasivan9Abhinav Menon10Mohammed Thabrez11Keechilat Pavithran12Department of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa VidyapeethamDepartment of Medical Oncology, Aster MedcityDepartment of Hepatology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa VidyapeethamDepartment of Medical Oncology, Aster MedcityDepartment of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa VidyapeethamDepartment of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa VidyapeethamDepartment of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa VidyapeethamDepartment of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa VidyapeethamDepartment of Hepatology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa VidyapeethamDepartment of Gastroenterology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa VidyapeethamDepartment of Medical Oncology, Aster MedcityDepartment of Medical Oncology, Aster MedcityDepartment of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa VidyapeethamAbstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies. Patients and methods All patients diagnosed with advanced HCC who received systemic therapy with atezolizumab bevacizumab as the first- or second-line therapy were included in the study. Data were collected retrospectively from two comprehensive cancer centres between September 2020 and May 2024 by accessing the medical records. As per the IMBrave 150 trial, patients were given atezolizumab 1200 mg and bevacizumab 15 mg/kg intravenously every 3 weeks. Demographic details, adverse events, and radiological data were collected. Results We included one hundred and four patients with a median age of 67 years. Majority of the patients had a compensated cirrhosis (n = 77; 74%), while Child Pugh class B cirrhosis was observed in 19 patients (18%), and class C cirrhosis in 3 patients (3%). The median OS was 14.8 (95% CI; 6.8 – 22.9) months and median PFS in the whole cohort was 6.2 months (95% CI; 2.5 – 9.9) monthsGlobally, hepatocellular carcinoma (HCC) ranks sixth in incidence and third among cancer-related dea. Conclusion The real-world OS and PFS rates were lower than those of the IMBrave trial, most likely because 43% of our patients did not meet the inclusion criteria. We conclude that the combination of atezolizumab and bevacizumab is a safe and effective option for patients with unresectable hepatocellular carcinoma patients with manageable toxicities.https://doi.org/10.1186/s12885-025-14400-9atezolizumabbevacizumabhepatocellular carcinomareal worldimmune checkpoint inhibitors |
| spellingShingle | Merin Babu Ashok Sebastian Komaranchath Arun Valsan Arun R. Warrier Rakesh MP Wesley M. Jose Nikhil K. Haridas Sumi Soman Manjima P. Nair Shine Sadasivan Abhinav Menon Mohammed Thabrez Keechilat Pavithran Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study BMC Cancer atezolizumab bevacizumab hepatocellular carcinoma real world immune checkpoint inhibitors |
| title | Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study |
| title_full | Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study |
| title_fullStr | Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study |
| title_full_unstemmed | Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study |
| title_short | Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study |
| title_sort | safety and efficacy of atezolizumab bevacizumab in unresectable hepatocellular carcinoma a multicentric study |
| topic | atezolizumab bevacizumab hepatocellular carcinoma real world immune checkpoint inhibitors |
| url | https://doi.org/10.1186/s12885-025-14400-9 |
| work_keys_str_mv | AT merinbabu safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT ashoksebastiankomaranchath safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT arunvalsan safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT arunrwarrier safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT rakeshmp safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT wesleymjose safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT nikhilkharidas safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT sumisoman safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT manjimapnair safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT shinesadasivan safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT abhinavmenon safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT mohammedthabrez safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy AT keechilatpavithran safetyandefficacyofatezolizumabbevacizumabinunresectablehepatocellularcarcinomaamulticentricstudy |